A lawsuit is challenging the policy of many employers and government programs that refuse to cover costly obesity medications. One patient is suing her insurance company, claiming discrimination on the basis of disability. Short sellers are increasing their bets against restaurant stocks due to concerns about weight-loss drugs like Ozempic. Danish drugmaker Novo Nordisk's share price has quadrupled in the past five years due to the success of its drugs Ozempic and Wegovy. The US FDA has warned online vendors to stop selling unapproved weight-loss drugs. Novo Nordisk has stopped a trial of Ozempic for kidney failure after early signs of success. Shares of dialysis providers have dropped following the success of Ozempic's kidney trial. JPMorgan predicts that medical-device stocks will be hit by the rising popularity of weight-loss drugs. Bank of America sees risks for employers as insurance coverage of weight-loss drugs grows. Lilly's bowel disease drug has succeeded in a late-stage study. Novo Nordisk warns of rising offers of fake Ozempic and Wegovy online. DaVita downplayed the impact of GLP-1 drugs like Ozempic on kidney patients.
Novo Nordisk warns online offers of fake Ozempic, Wegovy are rising https://t.co/i7cDKomXbz https://t.co/AsdHEw8YkG
DaVita downplayed the impact of GLP-1 drugs like Novo Nordisk’s Ozempic after study results in kidney patients sent the dialysis-provider’s stock tumbling https://t.co/p2MzyEQBCu
Which stocks might be disrupted next by Ozempic and other GLP-1 drugs https://t.co/5VYipwmPd3
Lilly's bowel disease drug succeeds in late-stage study https://t.co/U1gn5H9kcE https://t.co/9VClUaQrdy
$DVA (+2.0% pre) DaVita (DVA) Statement on GLP-1 and Potential Implications on Chronic Kidney Disease - SI https://t.co/xMmLEb2BfY
Australia's CSL tanks as Novo Nordisk's kidney trial success stokes competition concerns https://t.co/X7wUIMZ0nD https://t.co/qG5hM6o8OS
Ozempic Shows Kidney Promise in Blow to Dialysis Firms https://t.co/WYJmQyS9gO
The disruptive impact on stock markets of Novo Nordisk diabetes drugs is getting ever wider, rippling from snacks to booze and now touching kidney dialysis providers https://t.co/2FjMRzJsKK
JPMorgan sees medical-device stocks hard hit by the rising popularity of a new class of weight loss drugs as poised to extend their drop into year end https://t.co/FHSi9Pkymy
JPMorgan sees medical-device stocks hard hit by the rising popularity of a new class of weight loss drugs as poised to extend their drop into year end https://t.co/ScSH1HdmWA
Short sellers boost bets against restaurant stocks over concerns about higher interest rates and weight-loss drugs such as Ozempic https://t.co/DI4M8Z65Vn
How is the rise of GLP-1 weight loss drugs affecting market action? Jim Cramer explains https://t.co/3S2Kj8CjFj
No End in Sight for Ozempic-Fueled Drop in Medical-Device Stocks https://t.co/HxOCANeAfX
More employers could cover popular weight loss and diabetes drugs like Ozempic and Wegovy in 2024, allowing workers to avoid steep out-of-pocket costs, a new survey found. https://t.co/GaMRBOEjPS
The explosive impact on stock markets of Novo Nordisk diabetes drugs is getting ever wider, rippling from snacks to booze and now touching kidney dialysis providers https://t.co/vVd1BBVBd3
JPMorgan sees medical-device stocks hard hit by the rising popularity of a new class of weight loss drugs as poised to extend their drop into year end https://t.co/ol2Smoqh5L
JPMorgan sees medical-device stocks hard hit by the rising popularity of a new class of weight loss drugs as poised to extend their drop into year end https://t.co/Lu9Zjk5lTD
Rough day for medical device makers, on top of an ugly six months. https://t.co/BWRcCEzsGG
In Britain, overweight individuals are increasingly being denied insurance https://t.co/qDuE69Zvaj https://t.co/oJdqv9MSpN
Breakingviews - Obesity revolution gorges on dialysis maker https://t.co/bPcGQCc2VS
Having hard time believing, as a kidney doctor, that the data from Ozempic will have such an impact on CKD patients to the level dialysis stocks have reacted. While I believe it will delay CKD progression, a la gliflozin family, I doubt it will be curative. $DVA $NVO $LLY ...
Bank of America sees risks for employers as insurance coverage of weight loss drugs grows https://t.co/G2foAQBCGD
"Probably won't need MABs, genomics, or flu testing now that Ozempic works on kidneys." https://t.co/8aTBT5kfG9
Two pieces of news are weighing on shares of the medical devices company. https://t.co/aSIvZ15CVy
Jim Cramer praises Walgreens new CEO pick, says buy the stock 'perhaps aggressively' https://t.co/nrLcl3Gw0L
The explosive impact on stock markets of Novo Nordisk diabetes drugs is getting ever wider, rippling from snacks to booze and now touching kidney dialysis providers https://t.co/fNqNHZtMGR
$PEP Pepsi on impact of obesity drugs https://t.co/mNFbOJtY79
Novo Nordisk plans to stop a trial of Ozempic to treat kidney failure after an interim analysis showed the drug would succeed. https://t.co/kYnHMnG0a5
Breakingviews - Obesity revolution gorges on dialysis maker https://t.co/O5XXwkz34p
Novo Nordisk, Eli Lilly leap as Ozempic show promise in kidney patient treatment https://t.co/aK7OmrbGQu
On @Breakingviews: Shares of Fresenius Medical Care fell 20% after a trial showed a Novo Nordisk drug reduced the risk of kidney failure. It highlights how fast-growing weight-loss treatments will pummel other areas of medicine, writes @aimeedonnellan https://t.co/cQLTl9g2Iu
From Breakingviews - Obesity revolution gorges on dialysis maker https://t.co/jo51zlZG4q
$DVA (-15.6% pre) $FMS (-15.6% pre) $BAX (-8.8% pre) Shares of dialysis providers drop after Ozempic's early kidney trial success https://t.co/OetFxhloyW
$DVA (-15.6% pre) $FMS (-15.6% pre) $BAX (-8.8% pre) Shares of dialysis providers drop after Ozempic's early kidney trial success https://t.co/VNMl3mvLXB
$NVO (+3.7% pre) $LLY (+2.8% pre) Novo Nordisk, Eli Lilly leap as Ozempic shows promise in kidney patient treatment - The Street https://t.co/MswQocEX3n
Shares of dialysis providers drop after Ozempic's early kidney trial success https://t.co/2ip5djOdXw https://t.co/lnOg8ceanK
The explosive impact on stock markets of Novo Nordisk diabetes drugs is getting ever wider, rippling from snacks to booze and now touching kidney dialysis providers https://t.co/hInIj8FL0y
Novo Nordisk says its diabetes and weight loss drug Ozempic may also help tackle kidney failure https://t.co/QzgOZLKNYK
Short sellers boost bets against restaurant stocks over concerns about higher interest rates and weight-loss drugs such as Ozempic https://t.co/IFx15grJRA
Short sellers boost bets against restaurant stocks over concerns about higher interest rates and weight-loss drugs such as Ozempic https://t.co/67bA7ijhdc
I'm a morbidly obese woman and I'm suing my health insurer for $700,000 https://t.co/T9KARBMgFW https://t.co/FyuVtjPEOa
Jim Cramer says it's too soon to tell how GLP-1 weight loss drugs will affect food stocks https://t.co/B56gPZAm5M
Novo Nordisk stops Ozempic kidney trial after early signs of success https://t.co/m5EYBJpVWs https://t.co/fuyKLAhqfk
I'm a morbidly obese woman who is suing my health insurer for $700,000 because they refused to cover my weight-loss surgery https://t.co/yf8H1bFLP3 https://t.co/TjDMrXxbKQ
Many employers and government programs won’t cover costly obesity medications. One patient is trying to change that by suing, and arguing that she is being discriminated against on the basis of disability. https://t.co/PhkJaDL691
US FDA warns online vendors to stop selling unapproved weight-loss drugs https://t.co/mXELWpooNx https://t.co/dMEpu8feKI
Danish drugmaker Novo Nordisk’s share price has more than quadrupled in the past five years, making it Europe’s most valuable company by market cap. Why? Ozempic and Wegovy. https://t.co/PkhEQd1kXP https://t.co/5gC77irPxX
Breakingviews - Pepsi has long way to go to win Ozempic challenge https://t.co/nv7ak9MntV
Many employers and government programs won’t cover costly obesity medications. One patient is trying to change that by suing, and arguing that she is being discriminated against on the basis of disability. https://t.co/p9DFtH1Ro9
Breakingviews - Pepsi has long way to go to win Ozempic challenge https://t.co/UrGQBGXM8K
Pepsi/obesity drugs: snack pack will withstand economies of scales https://t.co/5NdT4oBlRU | opinion
Investors' fears that the new weight-loss drugs will hamstring Big Food companies are overblown. https://t.co/qShP7VTAzP
From Breakingviews - Pepsi has long way to go to win Ozempic challenge https://t.co/P0QDckPAHk
$NVO $LLY Her Insurance Refused to Pay for Wegovy, So She Sued: Many employers and government programs won’t cover costly obesity medications. A lawsuit is challenging one such policy. https://t.co/1ZJCc04P4j https://t.co/njBtqr8Nuu
Short sellers have increased their bets against restaurant stocks over concerns about higher interest rates and weight-loss drugs such as Ozempic, per Bloomberg.